Advertisement

Topics

Ultragenyx's hypophosphatemia drug succeeds in phase 3 study

05:22 EDT 20 Apr 2017 | Pharmaceutical Business Review

Ultragenyx Pharmaceutical, Kyowa Hakko Kirin and Kyowa Kirin International have reported positive 24-week data from the randomized, double-blind, placebo-controlled Phase 3 trial of burosumab (KRN23) in X-linked hypophosphatemia (XLH) adult patients.

Original Article: Ultragenyx's hypophosphatemia drug succeeds in phase 3 study

NEXT ARTICLE

More From BioPortfolio on "Ultragenyx's hypophosphatemia drug succeeds in phase 3 study"

Quick Search
Advertisement